Stanford, CANCT05139056Now EnrollingIRB Ready

Currently Only Enrolling Glioblastoma Patients at First Recurrence Clinical Trial in Stanford, CA

Access cutting-edge currently only enrolling glioblastoma patients at first recurrence treatment through this phase 1 clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.

Sponsored by City of Hope Medical Center

Quick Self-Assessment

See if you qualify for this Stanford location

Preparing your pre-screening questions…

Expert Care in Stanford

Access currently only enrolling glioblastoma patients at first recurrence specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related currently only enrolling glioblastoma patients at first recurrence treatment provided free

Apply for This Stanford Location

Check if you qualify for this currently only enrolling glioblastoma patients at first recurrence clinical trial in Stanford, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Stanford

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Stanford site if eligible
  4. 4Begin participation

About This Currently Only Enrolling Glioblastoma Patients at First Recurrence Study in Stanford

This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

Sponsor: City of Hope Medical Center

Who Can Participate

Inclusion Criteria

Patient must be age \>= 18 years
Patient has a Karnofsky performance status of \>= 70%
Patient has a life expectancy of \>= 3 months
When determining the maximum tolerated number of treatment cycles (MTC): patient has a histologically confirmed diagnosis of a grade 3 or 4 glioma (eg., glioblastoma, grade 4 astrocytoma, grade 3 astrocytoma, grade 3 oligodendroglioma). (This part of the study has been completed).
When enrolling to Treatment Schedules 4 and 4a: patient has glioblastoma at first recurrence.
Imaging studies show evidence of recurrent, supratentorial tumor(s).
Patient's high-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide
The patient must be in need of surgery for tumor resection
Based on the neurosurgeon's judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles
Absolute neutrophil count (ANC) of \>= 1000 cells/mm\^3
Platelet count \>= 100,000 cells/mm\^3
Total bilirubin =\< 2.0 mg/dl
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 4 times the institutional upper limit of normal
Serum creatinine =\< the institutional upper limit of normal
At least 2 weeks from taking the last dose of a targeted agent
At least 4 weeks from the last dose of bevacizumab For temozolomide, an interval of 23 days is required from the last dose administered if the patient was recently treated with adjuvant temozolomide, consisting of temozolomide daily for 5 days, repeated every 28 days.
At least 2 weeks from taking the last dose of a targeted agent.
At least 4 weeks from the last dose of bevacizumab.
All significant toxicities from previous anticancer therapy must have stabilized to a new baseline or resolved.
All participants must have the ability to understand and the willingness to sign a written informed consent.
The effects of this treatment on a developing fetus are unknown. Therefore, female patients of childbearing potential and sexually-active male patients or who are able to impregnate their partner, must agree to use an effective method of contraception while participating in this study. Patients of childbearing potential must have a negative pregnancy test =\< 2 week prior to registration.

Exclusion Criteria

Patient has multi-focal disease.
Patient is receiving radiation, chemotherapy, or another investigational agent.
Patient has had prior therapy with neural stem cells.
Patient has not recovered from any toxicity (\> grade 1) of prior therapies, except alopecia.
Patient is unable to undergo a brain MRI.
Patient has chronic or active viral infections of the central nervous system (CNS).
Patient has a coagulopathy or bleeding disorder.
Patient has an uncontrolled illness including ongoing or active infection.
Patient has another active malignancy.
Patient is pregnant or breastfeeding.
A patient has a serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stanford?

Yes, this clinical trial (NCT05139056) has an active research site in Stanford, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Currently Only Enrolling Glioblastoma Patients at First Recurrence Treatment Options in Stanford, CA

If you're searching for currently only enrolling glioblastoma patients at first recurrence treatment options in Stanford, CA, this clinical trial (NCT05139056) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stanford research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced currently only enrolling glioblastoma patients at first recurrence specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all currently only enrolling glioblastoma patients at first recurrence clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Stanford, CA

See all brain cancer clinical trials recruiting in Stanford — not just this study.

Browse Brain Cancer Trials in Stanford →

Browse More Trials by Condition

Brain Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Stanford?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Stanford, CA